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The miR-34 family was originally found to be a direct
target of p53 and is a group of putative tumor
suppressors. Surprisingly, mice lacking all mir-34
genes show no increase in cancer formation by
18 months of age, hence placing the physiological
relevance of previous studies in doubt. Here, we
report that mice with prostate epithelium-specific
inactivation of mir-34 and p53 show expansion of
the prostate stem cell compartment and develop
early invasive adenocarcinomas and high-grade
prostatic intraepithelial neoplasia, whereas no such
lesions are observed after inactivation of either the
mir-34 or p53 genes alone by 15 months of age.
Consistently, combined deficiency of p53 and
miR-34 leads to acceleration of MET-dependent
growth, self-renewal, and motility of prostate stem/
progenitor cells. Our study provides direct genetic
evidence that mir-34 genes are bona fide tumor
suppressors and identifies joint control of MET
expression by p53 and miR-34 as a key component
of prostate stem cell compartment regulation, aber-
rations in which may lead to cancer.
INTRODUCTION
The microRNA-34 (miR-34) is highly evolutionarily conserved
(Corney et al., 2007; He et al., 2007). In mammals, the miR-34
family is composed of three processed microRNAs (miRNAs)
that are encoded by two different genes: miR-34a is encoded
by its own transcript, whereas miR-34b and miR-34c share a
common primary transcript as a cluster. Due to the high homol-
ogy among these three members, they havemany similar targets
and may be functionally redundant (He et al., 2007). miR-34 was
the first miRNA reported to be directly transactivated by tumor
suppressor p53 (aka Trp53/TP53) and is considered to be an
important component of the p53 network (Hermeking, 2012).1000 Cell Reports 6, 1000–1007, March 27, 2014 ª2014 The AuthorsIn addition to a transactivation-dependent decrease in expres-
sion levels in p53-deficient tumors, mir-34 is also deleted or
epigenetically downregulated in multiple cancer cell lines and
human malignancies (Bader, 2012; Hermeking, 2012). Ectopic
expression of miR-34 has been shown to counteract various
oncogenic processes by regulating target genes that function
in cell cycle, apoptosis, senescence, cell migration, and invasion
(Hermeking, 2012). Furthermore, treatment with miR-34 mimics
inhibits cancer formation in transplantation experiments (Bader,
2012; Liu et al., 2011).
Contrary to the expectations raised from experiments based
on nonphysiological approaches, such as exogenous miR-34
introduction and miR-34 knockdown, only minor defects have
been reported in studies of mice with targeted inactivating
mutations of mir-34 (Concepcion et al., 2012; Wei et al., 2012).
Moreover, complete genetic inactivation of miR-34 did not
impair the p53 response in a variety of ex vivo and in vivo assays
(Concepcion et al., 2012). Most surprisingly, no increase in
spontaneous or irradiation-induced carcinogenesis has been
observed in mice lacking all mir-34 genes by 18 month of age
(Concepcion et al., 2012). The absence of all mir-34 genes also
did not accelerate B cell lymphomagenesis in mice overexpress-
ing c-Myc under the control of the Em promoter (Concepcion
et al., 2012). These data question the native tumor-suppressive
function of miR-34. Clarification of the miR-34 role as a tumor
suppressor is of particular importance because reintroduction
of this miRNA into cancer cells has already reached phase 1 clin-
ical trials (Bouchie, 2013).
A number of recent studies have provided evidence of p53-
independent expression of miR-34. For example, miR-34a can
be upregulated to repress MYC during oncogene-induced
senescence in human TIG3 fibroblasts (Christoffersen et al.,
2010) and contributes to megakaryocytic differentiation of
K562 cells (Navarro et al., 2009) in a p53-independent fashion.
Consistent with these observations, levels of all miR-34 family
members remain high in the brains, testes, and lungs of mice
lacking p53 (Concepcion et al., 2012).
Methylation of mir-34a and mir-34b/c has been found in
prostate cancers carrying mutant p53 (Fujita et al., 2008; Kojima
et al., 2010; Liu et al., 2011; Lodygin et al., 2008). Furthermore,
frequent hypermethylation of mir-34 in cancers with a high
occurrence of p53 mutations, such as ovarian and mammary
carcinomas and soft tissue sarcomas (Corney et al., 2010;
Lodygin et al., 2008; Vogt et al., 2011), suggests the coexistence
of both alterations in the same neoplasms. These findings,
together with reports of p53-independent regulation of miR-34,
suggest that p53 and miR-34 may cooperate in cancer suppres-
sion. This possibility is also supported by our observation
that p53 and miR-34 may jointly regulate MET receptor tyrosine
kinase as part of a coherent feedforward loop in primary ovarian
surface epithelium cells (Hwang et al., 2011). However, there is
no direct experimental evidence for p53 andmiR-34 cooperation
in MET regulation in animal models. By using newly generated
mice carrying conditional alleles of mir-34a and mir-34b/c, we
show that miR-34 cooperates with p53 in suppression of
prostate carcinogenesis by joint MET-mediated control of the
stem cell compartment.
RESULTS
miR-34 Cooperates with p53 in Suppression of Prostate
Carcinogenesis
By using gene targeting ofmir-34a andmir-34b/c loci (Figure S1)
and subsequent crosses of mice, we prepared mice with con-
ventional (mir-34a/mir-34b/c/) and conditional (floxed,
mir-34aloxP/loxPmir-34b/cloxP/loxP) triple knockout alleles and
designated them as mir-34/ and mir-34L/L, respectively.
Consistent with a previous report by Concepcion et al. (2012),
our findings indicate that germline genetic inactivation of
mir-34 has only a minor effect on normal development (Supple-
mental Results, Supplemental Discussion, and Figure S2). We
also have not observed any significant pathological phenotypes,
including cancers, in mir-34/ mice (n = 19) between 15 and
18 months of age.
To rule out the possibility that mice somehow physiologically
compensate for germline mir-34 deficiency, we performed
prostate epithelium-specific mir-34 deletion. This was accom-
plished by using a PB-Cre4 transgene, in which a modified
probasin promoter drives postnatal expression of Cre re-
combinase in the prostate epithelium (Chen et al., 2005;
Zhou et al., 2006). Consistent with previous reports and our
findings in mir-34/ mice, mice lacking all mir-34 genes in
the prostate epithelium cells (mir-34PE/ mice) did not show
any atypical lesions by 15 months of age (Figures 1A, 1B,
and S3A; Table S1).
To test if miR-34 may have p53-independent function, we
determined the expression levels of the miR-34 family after
p53 deletion in FACS-purified p53L/L prostate epithelium cells
exposed to Ad-Cre. Significant levels of miR-34 expression
were still detected after p53 inactivation (Figures S3B and S3C).
To test if p53 and miR-34 may cooperate in suppressing
prostate carcinogenesis we generated p53PE/ and p53PE/
mir-34PE/ mice by crossing p53L/L mice with mir-34L/L and
PB-Cre4 mice. Consistent with previous reports on lack or low
frequency of neoplastic lesions in mice with prostate epithe-
lium-specific p53 inactivation (Chen et al., 2005; Zhou et al.,
2006), only 1 out of 11 p53PE/ mice (9%) showed prostatic
intraepithelial neoplasia 1 (PIN1) by 9 months of age in theCedistal regions of prostatic ducts. By 15 months of age more of
p53PE/ mice developed PINs. However, all of them were of
low-grade (PIN1 or PIN2; Figures 1A, 1B, and S3A; Table S1).
No significant changes were observed in the proximal regions
of prostatic ducts, which are known to encompass a prostate
epithelium stem cell compartment (Leong et al., 2008; Tsujimura
et al., 2002).
In contrast, beginning at 3months of age p53PE/mir-34PE/
mice showed dysplastic lesions characterized by varying degree
of nuclear atypia and loss of normal cellular arrangement in the
proximal regions of prostatic ducts (Figures 1A and S3A; Table
S1). From 9 months of age majority of mice had advanced
dysplastic lesions which frequently filled up expanded ducts,
and 15% and 36% of mice developed early invasive adenocarci-
nomas at 9 and 15 months, respectively (Figures 1A and S3A;
Table S1). In the distal regions of prostatic ducts, the first PIN1
lesions were detected already by 3 months of age (Figures 1B
and S3A; Table S1). High-grade PIN lesions (PIN3 and 4) have
been observed by 9 months of age and 64% (9 out of 14) of
mice had such lesions at 15 months of age. Consistent with
these findings, adenocarcinomas and high-grade PIN lesions
of the proximal and distal regions of prostatic ducts, respec-
tively, characterized by elevated expression of markers of early
prostate cancer, such as AMACR and EZH2, and increased
number of CK5 and p63-positive cells (Figure 1C). Similarly,
higher proliferative activity has been observed in both proximal
and distal regions of prostatic ducts of p53PE/mir-34PE/
mice (Figures 1D and 1E). In summary, these results show that
miR-34 and p53 cooperate in suppression of prostate
carcinogenesis.
p53 and miR-34 Cooperate in the Control of Prostate
Stem/Progenitor Cell Activity
According to our pathological evaluation, the stem/progenitor
cell-enriched proximal regions of prostatic ducts were specif-
ically affected in p53PE/mir-34PE/ mice. To test if combined
p53 and miR-34 deficiency affects functional properties of
prostate stem/progenitor cells, we isolated such cells by fluo-
rescence-activated cell sorting (FACS) as a CD49fhi/Sca-1+
fraction. Mice with prostate-specific deletions of either mir-34
or p53 had slightly more stem/progenitor cells than back-
ground-matched wild-type (WT) mice (Figure 2A). However,
the pool of CD49fhi/Sca-1+ cells deficient for both miR-34
and p53 increased by 39% and constituted 7.1% of the pros-
tate epithelium versus 5.1% in WT. Notably, the CD49fhi/
Sca-1+ fraction isolated from the prostates of p53PE/mir-
34PE/ mice formed prostaspheres far more efficiently and
of larger size (Figures 2B and 2C). Both higher frequency and
the size of spheres formed by p53 and miR-34-deficient
CD49fhi/Sca-1+ stem/progenitor cells were maintained over
multiple passages (dissociation and clonal formation), suggest-
ing a role for these genes in the control of self-renewal. At the
same time, no difference among genotypes was observed in
CD49flo/Sca-1 luminal cells (Figure 2D). These cells formed
very few spheres after the first plating, and no spheres were
observed after the first passage. Thus, miR-34 and/or p53
deficiency is unlikely to reprogram differentiated cells toward
the stem cell state.ll Reports 6, 1000–1007, March 27, 2014 ª2014 The Authors 1001
(legend on next page)
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Figure 2. Deletions of Both p53 and mir-34
Promote Prostate Stem/Progenitor Cell
Expansion and Sphere-Forming Capacity
(A) A quantitative analysis of distribution of
CD49fhi/Sca-1+ stem/progenitor cells and
CD49flo/Sca-1 luminal cells from 3-month-old
WT, mir-34PE/, p53PE/, and p53PE/mir-
34PE/ mice (n = 3). Red and blue frames repre-
sent stem/progenitor cell and luminal cell pop-
ulations, respectively.
(B–D) The frequency (B and D) and size (C)
of spheres formed by CD49fhi/Sca-1+ stem/
progenitor cells (B and C) and CD49flo/Sca-1 (D)
luminal cells from 3-month-old WT, mir-34PE/,
p53PE/, and p53PE/mir-34PE/ mice (n = 3).
P0–P3, passages 0–3.
(E and F) The relative frequency of sphere forma-
tion by CD49fhi/Sca-1+ stem/progenitor cells (E)
and CD49flo/Sca-1 luminal cells (F) isolated from
WT, mir-34L/L, p53L/L, and p53L/Lmir-34L/L mice
followed by Ad-Cre infection (n = 3). Sphere
counts were normalized to the Ad-blank-infected
spheres of each passage.
**p < 0.01; ***p < 0.001. Error bars denote SD.To test whether the observed properties represent the direct
effects of p53 and/or miR-34 on prostate stem/progenitor
cells, we have isolated CD49fhi/Sca-1+ stem/progenitor cells
and CD49flo/Sca-1 luminal cells from the prostates of WT,
mir-34L/L, p53L/L, and p53L/Lmir-34L/L mice and, followed by
infection with Ad-Cre or Ad-blank, subjected them to the
prostasphere-formation experiments (Figures 2E and 2F). Con-
sistently, the lack of both p53 and miR-34 had the most
pronounced effect on the frequency of stem/progenitor cells
in consecutive passages.Figure 1. miR-34 and p53 Cooperate in Suppression of Prostate Carcinogenesis
(A and B) A quantitative analysis of the frequency of neoplastic lesions in proximal (A) and distal (B) regions of p
lesions; AC, adenocarcinoma; LG, low-grade PIN; HG, high-grade PIN.
(C) Proximal (left two columns) and distal (right two columns) regions of prostatic ducts in 15-month-old WT
invading the surrounding stroma (arrows) and filling up the lumen (arrowheads) in the proximal regions of th
shown. PIN4 (arrows) in the distal regions of the prostatic ducts of p53PE/mir-34PE/mice is shown. As co
adenocarcinomas and PIN4 (arrows) show higher expression levels of AMACR and EZH2 and an increased
toxylin and eosin staining. The ABC Elite method with hematoxylin (AMACR, CK5) or methyl green (EZH2, a
100 mm for all images.
(D and E) A quantitative analysis of the proliferation rate in proximal (D) and distal (E) regions of prostatic du
See also Figure S3A.
Cell Reports 6, 1000–1007p53 andmiR-34Regulation of Stem/
Progenitor Cells Depends on MET
In addition to the invasive growth of cells
in the prostate stem cell compartment
of p53PE/mir-34PE/ mice, we have
noted that some of the cells from the
p53 and miR-34-deficient prostaspheres
were spreading into the surrounding ma-
trix (Figure 3A). Because MET plays a
crucial role in regulation of cell motility
and invasion (Trusolino et al., 2010) and
is a known target of p53 (Hwang et al.,
2011) and miR-34 (Corney et al., 2010;He et al., 2007; Hwang et al., 2011), we have tested its expres-
sion in FACS-isolated populations of the prostate epithelium.
CD49fhi/Sca-1+ prostate stem/progenitor cells had far higher
levels of expression as compared to CD49flo/Sca-1luminal
cells (Figure 3B). Deficiency for either miR-34 or p53 slightly
increased MET levels in stem/progenitor cells, whereas such
cells from p53PE/mir-34PE/ showed the highest MET
expression (Figures 3B and 3C). Consistently, CD49fhi/Sca-1+
prostate stem/progenitor cells deficient for both miR-34 and
p53 had the highest motility in the migration assay (Figure 3D)rostatic ducts. N, normal; PRD, proximal dysplastic
and p53PE/mir-34PE/ mice. Adenocarcinomas
e prostatic ducts of p53PE/mir-34PE/ mice are
mpared to the prostate epithelium of WTmice, both
number of CK5 and p63-positive cells. HE, hema-
nd p63) counterstaining was performed. Scale bar,
cts. *p < 0.05; **p < 0.01. Error bars denote SD.
, March 27, 2014 ª2014 The Authors 1003
Figure 3. MET Expression Is Essential for the Increased Growth, Sphere-Forming Capacity, Motility, and Invasion of p53 and miR-34-
Deficient Prostate Stem/Progenitor Cells
(A–H) Prostasphere formation (A), western blot (B), and qRT-PCR (C) of Met expression, migration (D and F), and invasion (E and G) by CD49fhi/Sca-1+ stem/
progenitor cells (A–E) and CD49flo/Sca-1 luminal cells (B, F, and G) of 3-month-old WT,mir-34PE/, p53PE/, and p53PE/mir-34PE/ mice (n = 3). (A) Note
the outgrowth of cells from prostaspheres prepared from p53PE/mir-34PE/ mice (arrow). (H) MET expression in the cells of proximal and distal regions of
prostatic ducts of 3- and 15-month-oldWT,mir-34PE/, p53PE/, and p53PE/mir-34PE/mice is shown. MET expression (arrows) is detected in the proximal
regions of the prostatic ducts of 3- and 15-month-old p53PE/mir-34PE/mice and in the PIN4 of the distal region in 15-month-old p53PE/mir-34PE/mice.
PIN1 (arrowheads) in the distal regions of prostatic ducts lacks MET expression in both p53PE/ and p53PE/mir-34PE/ mice. The ABC Elite method with
hematoxylin counterstaining was performed. Scale bars, 100 mm.
(I–N) qRT-PCR (I) and western blot (J) of Met expression, prostasphere size (K), sphere-forming capacity (L), migration (M), and invasion (N) of CD49fhi/Sca-1+
stem/progenitor cells isolated from 3-month-old WT, p53PE/mir-34PE/, and p53PE/mir-34PE/MetPE/ mice (n = 3).
*p < 0.05; **p < 0.01; ***p < 0.001. Error bars denote SD.and some trend, albeit not statistically significant, toward
increased invasive activity (Figure 3E). To the contrary, luminal
cells deficient for p53 and/or miR-34 had no significant differ-
ences in their motility (Figure 3F) or invasion (Figure 3G).
Consistent with ex vivo results, we also observed
elevated levels of MET expression in cells of the proximal
regions of prostatic ducts of p53PE/mir-34PE/ mice, as
compared to WT mice and mice with inactivation of either
mir-34 or p53 (Figure 3H). MET expression was below detectable
levels in the epithelium of the distal regions of the prostatic
ducts in all strains. The only exception was elevated MET
expression in high-grade PINs in p53PE/mir-34PE/ mice,
suggesting a possible increase in the number of stem cell-like
cells in such lesions.
To test if MET overexpression is essential for the observed
phenotypes, Met was inactivated using a conditional MetL/L1004 Cell Reports 6, 1000–1007, March 27, 2014 ª2014 The Authorsallele. Met inactivation abrogated growth, sphere-forming ca-
pacity, cell motility, and invasion of p53 and miR-34-deficient
CD49fhi/Sca-1+ prostate stem/progenitor cells (Figures 3I–3N).
Effects of MET downregulation on growth, sphere-forming
capacity, cell motility, and invasion of WT prostate stem/
progenitor cells were less prominent (Figures 4A–4G), consistent
with the lower levels of MET expression in such cells. However,
2-fold induction of MET expression by hypoxia resulted in a
comparable increase of all the above parameters (Figures
4A–4G). Similar to p53/mir-34-inactivation experiments, this
phenotype was reversed after MET knockdown, indicating a
critical role for MET in prostate stem/progenitor cell regulation.
Previously, it has been shown that p53may negatively regulate
MET expression by the miR-34-mediated targeting of MET (Cor-
ney et al., 2010; He et al., 2007; Hwang et al., 2011). Supporting
these observations, we have detected the preserved 30 UTR
Figure 4. MET Is Essential for the Growth, Sphere-Forming Capacity, Motility, and Invasion of WT Prostate Stem/Progenitor Cells and Is
Partially Regulated by SP1 Interacting with p53
(A–G) qRT-PCR (A) and western blot (B and C) ofMet expression, prostasphere size (D), sphere-forming capacity (E), migration (F), and invasion (G) of CD49fhi/
Sca-1+ stem/progenitor cells isolated from 3-month-old WT mice (n = 3) and cultured under normoxic (20% O2, A, B, and D–G) and hypoxic (0.2% O2, A–G)
conditions. *p < 0.05; **p < 0.01; ***p < 0.001. Error bars denote SD. Very similar results were obtained in separate experiments with two different Met small
interfering RNAs (siRNAs).
(H and I) Coimmunoprecipitation of cell lysates with SP1 (H) or p53 (I) antibodies followed by western blot with p53 or SP1 antibodies, respectively (upper panels).
Samples of the same lysates were used for western blot with p53 or SP1 antibodies before immunoprecipitation (lower panels). CD49fhi/Sca-1+ stem/progenitor
cells isolated from 3-month-old WT mice (n = 3) were used. IP, immunoprecipitation. BIP, before immunoprecipitation.
(J) The effect of mithramycin A (100 nM) on MET expression of CD49fhi/Sca-1+ stem/progenitor cells isolated from 3-month-old WT, mir-34PE/, p53PE/,
and p53PE/mir-34PE/ mice (n = 3).carrying two binding sites for miR-34 in prostate stem/progenitor
cells (Figure S4). We have also reported that p53 also represses
MET expression by miR-34-independent inhibition of SP1 bind-
ing to the Met promoter in the ovarian surface epithelium cells
(Hwang et al., 2011). Consistent with this mechanism, MET
reciprocal coimmunoprecipitation experiments have shown
that p53 physically interacts with endogenous SP1 in the pros-
tate stem/progenitor cells (Figures 4H and 4I). Furthermore,
SP1 inhibition results in reduction of MET expression in the pros-
tate stem/progenitor cells deficient for either p53 or both miR-34
and p53, but not for miR-34 alone (Figure 4J).
DISCUSSION
Our study provides direct genetic proof that miRNAs of the
miR-34 family may act as tumor suppressors in concert with
other genes, such as p53. These findings offer a solid physiolog-
ical basis for the rational design of diagnostic and therapeuticCeapproaches. Because the lack of mir-34 genes alone is insuffi-
cient for cancer initiation, their downregulation is likely to occur
at some point during tumor progression. However, the preexis-
tence of mir-34 methylation in some normal cells cannot be
excluded. Further genomic studies in conjunction with animal
modeling should be able to address this question. Although
our current studies have been focused on prostate cancer,
tissue-specific inactivation of mir-34 and p53 in other tissues
will address likely interactions of these genes in other cell
lineages.
Our observations confirm the earlier findings that p53 may
negatively regulate MET expression by miR-34-mediated target-
ing of MET and by miR-34-independent inhibition of SP1 binding
to the MET promoter. Notably, according to our previous ex vivo
studies, inactivation of both mechanisms is required to achieve
the highest MET overexpression, cell motility, and invasion
(Hwang et al., 2011). Our present study supports this possibility
in an autochthonous model of cancer. Our findings alsoll Reports 6, 1000–1007, March 27, 2014 ª2014 The Authors 1005
show that miR-34 effects on MET regulation occur both in a
p53-dependent and -independent manner. Specific mecha-
nisms for p53-independent miR-34 regulation remain to be
determined.
Previous studies have shown that p53 and miR-34 affect
induced pluripotent stem cell reprogramming (Choi et al., 2011;
Krizhanovsky and Lowe, 2009). p53 mediates the onset of the
senescence of endothelial progenitor cells (Rosso et al., 2006)
and negatively regulates the proliferation and survival of neural
stem cells (Meletis et al., 2006). Constitutive p53 activation re-
sults in depletion of adult stem cells in bone marrow, brain,
and testes (Liu et al., 2010). It has been reported that ectopic
expression of miR-34a may inhibit prostate cancer-propagating
cells (also known as cancer stem cells or cancer-initiating cells)
and metastasis by directly repressing CD44 (Liu et al., 2011).
However, the role for miR-34 in regulation of normal adult stem
cells has been unclear. Our study fills this gap by showing that
miR-34 regulates prostate stem/progenitor cells in cooperation
with p53. It will be of interest to see if a similar cooperation of
miR-34 and p53 may play a role in the stem cell compartments
of other cell lineages.
It has been previously reported that prostate cancer-propa-
gating cells express MET, and depletion of MET results in a
decrease in prostasphere formation (Rajasekhar et al., 2011).
However, the direct role of MET in regulation of normal prostate
stem/progenitor cells andmechanisms controlling its expression
have been uncertain. Our studies on prostate cells collected
either in the early stages of carcinogenesis or immediately after
mir-34 and p53 inactivation provide a missing link between
normal biological functions of MET and promotion of aberrant
expansion of the stem/progenitor cell pool, whichmay eventually
lead to cancer. Considering that MET is particularly overex-
pressed in stem/progenitor cells lacking both p53 and miR-34,
its therapeutic targeting may be especially effective in p53 and
miR-34-deficient cancer cases.
Some cancers arise from stem/progenitor cells (Flesken-
Nikitin et al., 2013; Schepers et al., 2012), whereas others may
originate from more differentiated cells (Friedmann-Morvinski
et al., 2012). In our study, we have observed that neoplastic
lesions in the distal regions of prostatic ducts, which are mainly
populated by transit-amplifying and differentiated cells, never
progress to frank invasive adenocarcinomas. These findings
support observations in other models that cancers arising from
stem cell compartments are more aggressive (Flesken-Nikitin
et al., 2013). Our autochthonous mouse model of prostate can-
cer based on prostate epithelium-specific inactivation of p53
and mir-34 should provide a valuable tool for further elucidation
of the role of individual cell subpopulations in prostate cancer
pathogenesis.
EXPERIMENTAL PROCEDURES
Generation of Mice with mir-34 Conventional and Conditional
Targeted Mutations
All animal experiments were carried out in strict accordance with the recom-
mendations of the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the Institutional
Laboratory Animal Use and Care Committee at Cornell University. mir-34a
and mir-34b/c gene-targeting vectors were introduced into embryonic stem1006 Cell Reports 6, 1000–1007, March 27, 2014 ª2014 The Authorscells, and homologous recombinants were identified by positive/negative
selection and by a quantitative approach, respectively. After germline trans-
mission of the targeted allele, a FRT-flanked Neo cassette was excised by
crosses with FLPeR transgenic mice. The resulting mice carrying conditional
(floxed) alleles were crossed to EIIa-Cremice to obtain conventional null alleles
(Figures S1A and S1B). The lack of individual miR-34 family members was
confirmed by qRT-PCR of the brain and the prostate of mir-34/ mice
(Figure S1C).
Animal Phenotyping, Cell Culture, and Molecular Biological
Experiments
Pathological assessment, immunohistochemistry, and quantitative image
analysis were performed as described earlier (Hwang et al., 2011; Zhou
et al., 2006) and in the Supplemental Information. miRNA in situ hybridization,
cell culture, qRT-PCR, western blot analysis, and coimmunoprecipitation were
performed according to earlier established protocols (Corney et al., 2010;
Hwang et al., 2011) and are described in detail in the Supplemental
Information.
Statistical Analysis
Statistical analyses were performed with InStat 3.10 and Prism 6 software
(GraphPad). A two-tailed unpaired t test, direct Fisher’s tests, and a log rank
Mantel-Haenszel test were used as appropriate.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Results and Discussion,
Supplemental Experimental Procedures, four figures, and one table and
can be found with this article online at http://dx.doi.org/10.1016/j.celrep.
2014.02.023.
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